Survivin gene promoter polymorphism -31G/C as a risk factor for keratocystic odontogenic tumor development

European Journal of Oral Sciences

Volumn 120, Issue 1, 2012, Pages 9-13

  Andric, Miroslav ^a   Nikolic, Nada ^a   Boskovic, Marija ^a   Milicic, Biljana ^a   Skodric, Sanja ^a   Basta Jovanovic, Gordana ^a   Milasin, Jelena ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Keratocystic odontogenic tumor; Odontogenic keratocyst; Polymorphism; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; CYTOSINE; GUANINE; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; MANDIBLE TUMOR; MIDDLE AGED; MOUTH MUCOSA; ODONTOGENIC TUMOR; PATHOLOGY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CYTOSINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GUANINE; HOMOZYGOTE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MANDIBULAR NEOPLASMS; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; ODONTOGENIC TUMORS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; YOUNG ADULT;

EID: 84856509467     PISSN: 09098836     EISSN: 16000722     Source Type: Journal    
DOI: 10.1111/j.1600-0722.2011.00919.x     Document Type: Article

References (32)

1. Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005; WHO classification of tumours series.
2. Myoung H, Hong SP, Hong SD, Lee JI, Lim CY, Choung PH, Lee JH, Choi JY, Seo BM, Kim MJ. Odontogenic keratocyst: review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 328-333.
3. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3: 32.
4. Peukert S, Miller-Moslin K. Hedgehog signaling pathway inhibitors as cancer therapeutics. Annu Rep Med Chem 2009; 44: 323-337.
5. Shear M, Speight PM. Odontogenic keratocyst. In: Shear M, Speight PM, ed. Cysts of the Oral and Maxillofacial Regions, Oxford: Blackwell Munksgaard, 2007; 6-58.
6. Lo Muzio L, Staibano S, Pannone G, Bucci P, Nocini PF, Bucci E, De Rosa G. Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome. J Dent Res 1999; 78: 1345-1353.
7. Kichi E, Enokiya Y, Muramatsu T, Hashimoto S, Inoue T, Abiko Y, Shimono M. Cell proliferation, apoptosis and apoptosis-related factors in odontogenic keratocysts and in dentigerous cysts. J Oral Pathol Med 2005; 34: 280-286.
8. Duffy MJ, O'donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007; 249: 49-60.
9. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
10. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
11. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, De Kok JB. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004; 50: 1986-1993.
12. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggiò MA, Procaccini M, Ferrari F, De Rosa G, Altieri DC. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003; 89: 2244-2248.
13. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, De Lillo A, Carinci F. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 2005; 225: 27-33.
14. Kumamoto H, Ooya K. Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. Virchows Arch 2004; 444: 164-170.
15. Andric M, Dozic B, Popovic B, Stefanovic D, Basta-Jovanovic G, Djogo N, Andjus P, Milasin J. Survivin expression in odontogenic keratocysts and correlation with cytomegalovirus infection. Oral Dis 2010; 16: 156-159.
16. De Oliveira MG, Da Silva Lauxen I, Chaves AC, Rados PV, Sant'ana Filho M. Odontogenic epithelium: immunolabeling of Ki-67, EGFR and Survivin in pericoronal follicles, dentigerous cysts and keratocystic odontogenic tumors. Head Neck Pathol 2011; 5: 1-7.
17. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; (Pt 2) 344: 305-311.
18. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004; 23: 527-537.
19. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 2011; 18: 880-887.
20. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009; 24: 145-150.
21. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE, Jung TH, Park JY. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008; 60: 31-39.
22. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Sato S, Mitobe Y, Narita S, Habuchi T. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 2011; 129: 1872-1880.
23. Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, Dong H, Sun Q, Cong R, Chen G, Wang B. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009; 54: 1021-1028.
24. Barreto DC, Gomez RS, Bale AE, Boson WL, De Marco L. PTCH gene mutations in odontogenic keratocysts. J Dent Res 2000; 79: 1418-1422.
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
26. Sengüven B, Oygür T. Investigation of interleukin-1 alpha and interleukin-6 expression and interleukin-1 alpha gene polymorphism in keratocystic odontogenic tumors and ameloblastomas. Med Oral Patol Oral Cir Bucal 2011; 16: e467-e472.
27. Wagner M, Schmelz K, Dörken B, Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 2008; 32: 1054-1060.
28. Borbély AA, Murvai M, Szarka K, Kónya J, Gergely L, Hernádi Z, Veress G. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007; 60: 303-306.
29. Borges BD, Burbano RR, Harada ML. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 2011; 11: 189-193.
30. Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, Yang K, Bai Y. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009; 135: 1341-1349.
31. Srivastava K, Srivastava A, Mittal B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 2011 May 26. [Epub ahead of print] DOI.
32. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst) 2010; 33: 177-189.